advertisement
Tsui E 31
Showing records 1 to 25 | Display all abstracts from Tsui E128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Fraser AS
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Kim IM
JAMA network open 2025; 8: e2521150
127679 Suprachoroidal Triamcinolone Acetonide for the Management of Retinal Vasculitis
Yamamoto M; Hanson J
Ocular Immunology and Inflammation 2025; 0: 1-6
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Ang M
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Radgoudarzi N
JAMA network open 2025; 8: e2521150
127679 Suprachoroidal Triamcinolone Acetonide for the Management of Retinal Vasculitis
Popovic M
Ocular Immunology and Inflammation 2025; 0: 1-6
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Bellchambers A
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Chen EM
JAMA network open 2025; 8: e2521150
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Chu CJ
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Liu J
JAMA network open 2025; 8: e2521150
127679 Suprachoroidal Triamcinolone Acetonide for the Management of Retinal Vasculitis
Palochak C; Hou K
Ocular Immunology and Inflammation 2025; 0: 1-6
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Denniston AK
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Moussa K
JAMA network open 2025; 8: e2521150
127679 Suprachoroidal Triamcinolone Acetonide for the Management of Retinal Vasculitis
McCannel C
Ocular Immunology and Inflammation 2025; 0: 1-6
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Downie LE
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Shantha JG
JAMA network open 2025; 8: e2521150
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Evans T
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Tsui E
JAMA network open 2025; 8: e2521150
127679 Suprachoroidal Triamcinolone Acetonide for the Management of Retinal Vasculitis
Chen JL; Tsui I
Ocular Immunology and Inflammation 2025; 0: 1-6
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Hau S
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Gore C
JAMA network open 2025; 8: e2521150
127679 Suprachoroidal Triamcinolone Acetonide for the Management of Retinal Vasculitis
Tsui E
Ocular Immunology and Inflammation 2025; 0: 1-6
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Huang AS
JAMA ophthalmology 2025; 143: 749-757
128651 Time to Progression to Proliferative Diabetic Retinopathy in Patients With Type 2 Diabetes
Baxter SL
JAMA network open 2025; 8: e2521150
128622 Proposed Nomenclature for Landmarks in Anterior-Segment OCT: The APOSTEL-AS Panel Consensus
Keane PA
JAMA ophthalmology 2025; 143: 749-757
